[go: up one dir, main page]

MX2021003653A - Inositol fosfatos para el tratamiento de calcificacion ectopica. - Google Patents

Inositol fosfatos para el tratamiento de calcificacion ectopica.

Info

Publication number
MX2021003653A
MX2021003653A MX2021003653A MX2021003653A MX2021003653A MX 2021003653 A MX2021003653 A MX 2021003653A MX 2021003653 A MX2021003653 A MX 2021003653A MX 2021003653 A MX2021003653 A MX 2021003653A MX 2021003653 A MX2021003653 A MX 2021003653A
Authority
MX
Mexico
Prior art keywords
treatment
calcifications
inositol
inositol phosphate
inositol phosphates
Prior art date
Application number
MX2021003653A
Other languages
English (en)
Inventor
Bestard Joan Perelló
Roca Carolina Salcedo
Hamann Ana- Zeralda Canals
Original Assignee
Sanifit Therapeutics S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanifit Therapeutics S A filed Critical Sanifit Therapeutics S A
Publication of MX2021003653A publication Critical patent/MX2021003653A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación se relaciona con composiciones, métodos, dosis, pautas posológicas, artículos de fabricación y kits para el tratamiento y/o la prevención de calcificaciones ectópicas y, en particular, calcificaciones cutáneas tales como calcificaciones debidas a calcifilaxia que comprenden inositol fosfato, análogos de inositol fosfato, derivados de inositol fosfato o combinaciones de estos. En un aspecto particular, la divulgación proporciona una pauta posológica para tratar la calcifilaxia que comprende la administración de 6 mg/kg a 9 mg/kg de dosis diarias de mio-inositol hexafosfato, tres veces por semana, durante al menos 1 a 8 meses.
MX2021003653A 2018-10-11 2018-10-11 Inositol fosfatos para el tratamiento de calcificacion ectopica. MX2021003653A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201830988A ES2754280A1 (es) 2018-10-11 2018-10-11 Pautas posológicas de IP y análogos de IP para el tratamiento de calcificaciones ectópicas
PCT/IB2018/057904 WO2020074944A1 (en) 2018-10-11 2018-10-11 Inositol phosphates for the treatment of ectopic calcification

Publications (1)

Publication Number Publication Date
MX2021003653A true MX2021003653A (es) 2021-06-23

Family

ID=64109944

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021003653A MX2021003653A (es) 2018-10-11 2018-10-11 Inositol fosfatos para el tratamiento de calcificacion ectopica.
MX2024005721A MX2024005721A (es) 2018-10-11 2021-03-26 Inositol fosfatos para el tratamiento de calcificacion ectopica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024005721A MX2024005721A (es) 2018-10-11 2021-03-26 Inositol fosfatos para el tratamiento de calcificacion ectopica.

Country Status (9)

Country Link
US (2) US10973838B2 (es)
KR (3) KR20240110085A (es)
CN (3) CN112839661A (es)
AU (1) AU2018445164B2 (es)
BR (1) BR112021006004A2 (es)
CA (1) CA3113377A1 (es)
ES (1) ES2754280A1 (es)
MX (2) MX2021003653A (es)
WO (1) WO2020074944A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112839661A (zh) * 2018-10-11 2021-05-25 萨尼菲特治疗有限公司 用于治疗异位钙化的肌醇磷酸酯类
WO2024023359A1 (en) * 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL132418C (es) 1962-04-13
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US5330979A (en) 1984-10-23 1994-07-19 Perstorp Ab Method of treating renal disorders with inositoltriphosphate
US4826675A (en) 1988-02-17 1989-05-02 Colgate-Palmolive Company Anticalculus oral composition
JPH01294631A (ja) 1988-05-19 1989-11-28 Sanwa Kagaku Kenkyusho Co Ltd 糖尿性疾患治療予防剤及び飲食、し好物
US5041429A (en) 1988-06-01 1991-08-20 Sanwa Kagaku Kenkyusho Co., Ltd. Cell activators, circulatory ameliorators and edible compositions
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5206226A (en) 1990-10-24 1993-04-27 Robert Sabin Method of treatment of Parkinsons's disease using phytic acid
US5112814A (en) 1990-10-24 1992-05-12 Robert Sabin Method of treatment of Parkinson's disease using phytic acid
AU668386B2 (en) 1992-03-25 1996-05-02 Depomed Systems, Incorporated Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5362886A (en) 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
AU729529B2 (en) 1997-06-06 2001-02-01 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
DE29910454U1 (de) 1999-06-10 1999-09-23 Vitasyn GmbH, 10789 Berlin Mittel zur Therapie von Hyperphosphatämie
AU781718B2 (en) 1999-11-02 2005-06-09 Depomed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
DE60123384T2 (de) 2000-02-04 2007-08-02 DepoMed, Inc., Menlo Park Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6610702B2 (en) 2000-08-01 2003-08-26 Gmp Oxycell, Inc. Ammonium salts of inositol hexaphosphate, and uses thereof
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
US20030031711A1 (en) 2001-05-29 2003-02-13 Fara John W. Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
EP1438027A1 (en) 2001-10-25 2004-07-21 DepoMed, Inc. Methods of treatment using a gastric retained losartan dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20070148258A1 (en) 2003-10-28 2007-06-28 O'neill W C Dialysates and methods and systems related thereto
ES2232302B1 (es) * 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
US20070212449A1 (en) 2006-03-02 2007-09-13 Shamsuddin Abulkalam M Reduction of the titratable acidity and the prevention of tooth and other bone degeneration
MX2008011553A (es) 2006-03-09 2008-12-09 Waratah Pharmaceuticals Inc Formulacion de polialcohol de ciclohexano para el tratamiento de transtornos de agregacion de proteinas.
ES2288126B2 (es) 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
ES2332636B1 (es) * 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
US20110091440A1 (en) 2009-03-27 2011-04-21 Robert Sabin Prophylactic and therapeutic treatment of neuro-degenerative diseases and protein aggregation diseases
PL2416770T3 (pl) 2009-04-06 2017-06-30 Crearene Ltd. Roztwory do hemodializy i dializy otrzewnowej zawierające jeden lub więcej związków kreatyny
US20110293595A1 (en) 2010-03-26 2011-12-01 Robert Sabin Prophylactic and therapeutic treatment of Alzheimer's Disease, neuro-degenerative diseases, protein aggregation diseases, Parkinson's Disease and amyloid diseases, using phytic acid and phytate
US8277909B2 (en) 2010-10-22 2012-10-02 Carestream Health, Inc. Transparent ink-jet recording films, compositions, and methods
US9751903B2 (en) * 2011-09-29 2017-09-05 Eth Zurich Pharmaceutical compounds for use in the therapy of clostridium difficile infection
CN105949234B (zh) 2011-09-29 2018-07-10 苏黎世联邦理工学院 用于治疗艰难梭菌感染的药物化合物
EP2579036A1 (en) 2011-10-06 2013-04-10 Laboratorios Sanifit, S.L. Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
US20130302448A1 (en) 2012-05-10 2013-11-14 Guy Parc Phytin aqueous solution and use of said solution for the preparation of a liquid nutritional supplement or a cosmetic composition
JP2015516407A (ja) 2012-05-10 2015-06-11 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 異所性石灰化の治療のためのチオ硫酸ナトリウム
US9364490B2 (en) * 2013-03-15 2016-06-14 Laboratoris Sanifit, S.L. Use of derivatives containing C—O—P bonds in patients with kidney failure
CN108367080B (zh) * 2015-12-11 2021-10-08 苏黎世联邦理工学院 用于病理性结晶的肌醇衍生物
EP3386994B1 (en) 2015-12-11 2019-12-11 ETH Zürich 4,6-di-(o-thiophosphate)-inositol-1,2,3,5-tetra-o-sulfate for c. difficile infection
ITUB20160180A1 (it) 2016-01-27 2017-07-27 Lo Li Pharma Srl Somministrazione topica/locale di inositolo esafosfato come coadiuvante nei trattamenti antitumorali
TWI730039B (zh) 2016-01-29 2021-06-11 日商富士藥品股份有限公司 新穎雙膦酸化合物
WO2017147521A1 (en) 2016-02-24 2017-08-31 Innovative Surface Technologies, Inc. Crystallization inhibitor compositions for implantable urological devices
WO2017192200A1 (en) 2016-05-05 2017-11-09 The Research Foundation For The State Unversity Of New York Compositions for treating periodontitis and dental calculus accumulation
CN112839661A (zh) * 2018-10-11 2021-05-25 萨尼菲特治疗有限公司 用于治疗异位钙化的肌醇磷酸酯类
EP3818983A1 (en) * 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification

Also Published As

Publication number Publication date
CA3113377A1 (en) 2020-04-16
CN120131675A (zh) 2025-06-13
KR102683836B1 (ko) 2024-07-09
US20200179422A1 (en) 2020-06-11
AU2018445164B2 (en) 2025-05-29
KR20240110085A (ko) 2024-07-12
WO2020074944A1 (en) 2020-04-16
CN112839661A (zh) 2021-05-25
KR20240042554A (ko) 2024-04-02
KR20210076904A (ko) 2021-06-24
CN120168489A (zh) 2025-06-20
US20210290642A1 (en) 2021-09-23
KR102651652B1 (ko) 2024-03-26
US12070469B2 (en) 2024-08-27
US10973838B2 (en) 2021-04-13
MX2024005721A (es) 2024-05-27
AU2018445164A1 (en) 2021-04-22
BR112021006004A2 (pt) 2021-06-29
ES2754280A1 (es) 2020-04-16

Similar Documents

Publication Publication Date Title
NZ751418A (en) Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
BR112019006047A2 (pt) compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica
SG10201811128RA (en) Ezh2 inhibitors for treating lymphoma
NZ722326A (en) Tricyclic compounds as anticancer agents
GB201205669D0 (en) Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
MX2019003363A (es) Composiciones farmaceuticas para usarse en la terapia de la blefaritis.
CO2018004206A2 (es) Formulación farmacéutica para administración oral que comprende un compuesto de 25-hidroxi vitamina d”
MX2016005396A (es) Composiciones para administracion oral de acido zoledronico o compuestos relacionados para tratar enfermedades.
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
BR112018068784A2 (pt) método para o tratamento de leucemia
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
MX2021003653A (es) Inositol fosfatos para el tratamiento de calcificacion ectopica.
MX389786B (es) Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer.
MX2022004971A (es) Compuestos de fosfato de inositol para su uso en el tratamiento, la inhibicion de la evolucion o la prevencion de la calcificacion cardiovascular.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
SG10201907289VA (en) Monomethylfumarate prodrug compositions
AU2018256668A1 (en) Combination therapy comprising an inhibitor of JAK, CDK and PIM
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
EA032654B9 (ru) [1,2,4]ТРИАЗОЛО[4,3-b]ПИРИДАЗИНЫ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
WO2020141828A3 (en) Anticancer compositions comprising immune checkpoint inhibitors
EA202092008A1 (ru) Противораковые фармацевтические композиции для комплексной терапии
AR102308A1 (es) Composición farmacéutica para usar en el tratamiento o prevención de deficiencias de vitaminas y minerales en pacientes sometidos a cirugía de bypass gástrico
BR112015012497A8 (pt) combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial
MX2022006179A (es) Derivados macrociclicos de indol como inhibidores de mcl-1.
ZA201906153B (en) Pharmaceutical compositions for combination therapy